Infigratinib is a targeted medication used for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. Its indication is limited to patients confirmed to have FGFR2 gene fusions or other rearrangements through FDA-approved detection methods. As a prescription drug under special management, there are strict regulations on its purchase channels, usage precautions, and authenticity identification.
How to Purchase Infigratinib
Overseas Purchase
Patients may choose to consult and purchase the medication at hospital pharmacies or legitimate drugstores in countries or regions where Infigratinib has been launched.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.
Purchase through Medical Service Institutions
Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions usually provide legal import channels and can offer professional consultation and guidance.
Precautions for Purchasing Infigratinib
Medical Evaluation Before Medication Use
Confirmation by genetic testing: The presence of FGFR2 gene fusion must be confirmed through FDA-approved detection methods.
Liver function test: For mild liver impairment, the dose needs to be adjusted to 100 mg per day; for moderate impairment, the dose needs to be adjusted to 75 mg per day.
Renal function test: For mild to moderate renal impairment, the dose needs to be adjusted to 100 mg per day.
Confirmation of Dosage Form and Specification
25 mg capsule: Opaque white body and opaque gray cap, printed with black text "INFI 25 mg".
100 mg capsule: Opaque white body and opaque light orange cap, printed with black text "INFI 100 mg".
Notification of Drug Interactions
Strong or moderate CYP3A inhibitors (e.g., itraconazole): Concomitant use should be avoided.
Strong or moderate CYP3A inducers (e.g., rifampicin): Concomitant use should be avoided.
Gastric acid reducers (e.g., proton pump inhibitors): Concomitant use should be avoided; if necessary, they should be taken at intervals.
Methods for Identifying the Authenticity of Infigratinib
Characteristics of Outer Packaging
The packaging box has exquisite printing and uniform colors.
The English trade name "TRUSELTIQ" is clear.
The label "Rx only" is marked.
Manufacturer information of QED Therapeutics is provided.
Characteristics of 25 mg Capsules
Opaque white body and opaque gray cap.
Printed with black text "INFI 25 mg".
The capsule size meets the standard.
Characteristics of 100 mg Capsules
Opaque white body and opaque light orange cap.
Printed with black text "INFI 100 mg".
The capsule size meets the standard.
